Agilent Technologies Ventures

Agilent Technologies Ventures is the strategic investment arm of Agilent, the Santa Clara analytical instruments company. The fund backs novel analytical laboratory technologies and life science diagnostics, reflecting Agilent’s core franchises in chromatography, mass spectrometry, genomics, pathology, and cell analysis. Founders working on sample preparation, reagents, novel detection chemistries, NGS workflows, single-cell tools, digital pathology, and clinical diagnostics that complement Agilent’s instrument platform should find thesis alignment. The corporate setting means investment decisions weigh both technical merit and strategic relevance to Agilent’s roadmap.

The fund invests at Seed and Series A with check sizes of $1M to $5M, making it relatively early-stage friendly compared to other large life sciences corporate VCs. It is based in the United States and concentrates on life sciences tools and diagnostics. No AI focus is stated.

Founders should approach with clarity on how their technology integrates with or extends Agilent’s instrument and consumables ecosystem. Evidence of technical differentiation, customer validation in academic or pharma labs, and a credible regulatory plan for diagnostics product candidates strengthens positioning. Limited public information is available about partner contacts and detailed portfolio composition, so warm introductions via Agilent business development, R&D leaders, or KOL scientists in the relevant analytical domain are typically the most effective entry path.